Skip to main content

Incyte Sues Invitrogen for Patent Infringement

SAN FRANCISCO, Nov. 28 – Contending patent violations, Incyte Genomics filed suit against Invitrogen on Nov. 21 in the US District Court of the Southern District of California.

The lawsuit follows Invitrogen’s own patent violations suit against Incyte , filed Oct. 17 in the US District Court of Delaware. 

Incyte’s lawsuit contends multiple patent violations, including infringements against gene patents in connection with Invitrogen’s GeneStorm Clones product, RNA amplification and gene expression analysis, and microarray fabrication, according to the complaint filed with the court.

Incyte, which said in court papers that “Invitrogen’s infringements of the… patents has been willful and deliberate” said Incyte “has been and continues to be damaged in its collective business and property, including the loss of substantial profits in an amount to be determined at trial.”

“As [the claims of patent infringement] relates to our GeneStorm clones, it appears to apply to only a dozen of the thousands of clones we sell,” Paul Goodson, vice president of investor relations at Carlsbad, Calif.-based Invitrogen, told GenomeWeb . “As it relates to other technologies, we think either we didn’t infringe, they are not valid, or they are unenforceable.” 

“We sued them not too long ago,” added Goodson. “We think this suit they have filed is a defensive tactic.”

Incyte declined to comment.

Incyte, based in Palo Alto, Calif., is currently undergoing a company-wide restructuring, including the announcement in October of approximately 400 layoffs and the appointment earlier this week of a new CEO and president

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.